Join Growin Stock Community!

Estrella immunopharma, inc.ESLA.US Overview

US StockHealthcare
(No presentation for ESLA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ESLA AI Insights

ESLA Overall Performance

ESLA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ESLA Recent Performance

-4.10%

Estrella immunopharma, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ESLA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ESLA Key Information

ESLA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ESLA Profile

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Price of ESLA

ESLA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ESLA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
241.30
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
241.30
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ESLA's latest earnings report released?

    The most recent financial report for Estrella immunopharma, inc. (ESLA) covers the period of 2026Q1 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ESLA's short-term business performance and financial health. For the latest updates on ESLA's earnings releases, visit this page regularly.

  • How much cash does ESLA have?

    At the end of the period, Estrella immunopharma, inc. (ESLA) held Total Cash and Cash Equivalents of 1.63M, accounting for 0.46 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ESLA's EPS continuing to grow?

    According to the past four quarterly reports, Estrella immunopharma, inc. (ESLA)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.13. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ESLA?

    Estrella immunopharma, inc. (ESLA)'s Free Cash Flow (FCF) for the period is -727.33K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 67.2% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.